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Abstract 
Protein tyrosine phosphatase PTPN13, also known as PTP-BL in mice, represents 
a large multi domain non-transmembrane scaffolding protein that contains five 
consecutive PDZ domains. Here, we report the solution structures of the extended 
murine PTPN13 PDZ3 domain in its apo form and in complex with its physiological 
ligand, the carboxy-terminus of PRK2, determined by multidimensional NMR 
spectroscopy. Both in its ligand-free state and when complexed to PRK2, PDZ3 of 
PTPN13 adopts the classical compact, globular D/E fold. PDZ3 of PTPN13 binds 
five carboxy-terminal amino acids of PRK2 via a groove located between the EB-
strand and the DB-helix. The PRK2 peptide resides the canonical PDZ3 binding 
cleft in an elongated manner and the amino acid side chains in position P0 and P-2, 
cysteine and aspartate, of the ligand face the groove between EB-strand and DB-
helix, whereas the PRK2 side chains of tryptophan and alanine located in position 
P-1 and P-3 point away from the binding. These structures are rare examples of 
selective class III ligand recognition by a PDZ domain and now provide a basis for 
the detailed structural investigation of the promiscuous interaction between the PDZ 
domains of PTPN13 and of their interaction with ligands. They will also lead to a 
better understanding of the proposed scaffolding function of these domains in multi-
protein complexes assembled by PTPN13 and could ultimately contribute to low 
molecular weight antagonists that could even act on the protein kinase C-related 
kinase-2 (PRK2) signalling pathway to modulate rearrangements of the actin 
cytoskeleton. 
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Introduction 
The protein tyrosine phosphatase PTPN13 and its mouse homologue, PTP-
basophil-like (PTP-BL), are high molecular non-transmembraneous protein 
phosphatases that contain various protein-protein interaction modules. The amino-
terminal part of murine PTPN13 (UNIPROT Q64512) consists of a KIND (kinase 
non-catalytic C-lobe; residues 3-190) domain, followed by a FERM (Four point one, 
Ezrin, Radixin, Moesin; residues 565-865) domain that is involved in the association 
of proteins to the plasma membrane. In addition, PTPN13 contains five PDZ 
domains (PDZ1: residues 1084-1170; PDZ2: residues 1357-1442; PDZ3: residues 
1491-1579; PDZ4: residues 1764-1845; PDZ5: residues 1857-1942) as well as a 
carboxy-terminal protein tyrosine phosphatase domain (residues 2180-2434) [1]. 
While structures of PDZ2b of PTPN13 and PDZ2 of PTPN13 have been solved, the 
structure of the PDZ3 domain still remained elusive to date [2], [3]. PDZ domains 
VKDUHDJOREXODUIROGWKDWFRQVLVWVRIWZRĮ-KHOLFHV'$DQG'%DQGȕ-strands 
(EA to EF), which form two anti-SDUDOOHOȕ-sheets [4], [5]. PDZ domains are well-
known to mediate protein-protein interactions and are crucial for the assembly of a 
number of multiprotein complexes [6]. Currently, a large number of PTPN13 
interacting proteins are already known and it is of great interest to further 
characterise binding properties of the PDZ domain module located in PTPN13. For 
example, it was shown that PDZ1 of PTPN13 binds to ImBc [7], [8], [9]. In addition, 
only one of the two splicing variants of PDZ2 interacts with the tumour suppressor 
protein APC (adenomatous polyposis coli), whereas PDZ3 associates with the 
protein kinase PRK2 [1], [27]. It is also known that one of the proteins that interacts 
with PDZ4 of PTPN13 is CRIP2, a LIM-only protein (for a review see [1]. PDZ 
domains 2, 3, and 5 are also capable of binding the phospholipid 
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phosphatidylinositol-4,5-bisphosphate [10]. Interestingly, PTPN13 is not the only 
protein that contains multiple PDZ domains. For instance, the membrane-
associated guanylate kinase (MAGUK) family of proteins carries several, mostly 
class I PDZ domains in addition to other protein binding modules, such as SH3 and 
WW domains [11], [12]. Like PTPN13, MAGUK proteins serve as scaffolding 
proteins that associate to transmembrane tight-junction-associated proteins, the 
cytoskeleton, and signal transduction molecules [12]. MAGUK proteins use a 
combination of several modular domains that yield complex scaffolding functions at 
different subcellular, cellular, and even systems level [11]. Apparently, cooperative 
effects in multi-domain PDZ proteins modulate their affinity towards ligands bearing 
a PDZ-ligand binding motif (PBM). 
 PDZ domains serve as interaction modules that gather functionally distinct 
proteins in order to form multifunctional supramolecular complexes. Therefore, PDZ 
(PSD-95, discs large, Zonula occludens) domain-containing proteins are frequently 
denoted as scaffolding proteins that selectively bind to the carboxy-termini of their 
protein targets. PSD95, for instance, is a membrane-associated member of the 
guanylate kinase family of proteins that binds to neuronal glutamate receptors to 
form a macromolecular complex [13], [14]. The PDZ domain-containing proteins 
Afadin and ZO1 interact with the cytoskeleton and stabilise cells and tissue [15], 
[16]. To date, numerous structures of PDZ-ligand complexes have been solved 
either by NMR spectroscopy or X-ray crystallography providing fundamental 
insights into the molecular mechanisms of how PDZ domains recognise and 
stabilise their bound ligands [17]. PDZ domains are classified according to their 
binding specificity towards certain C-terminal binding motifs of their potential 
binding partners. A sequence alignment of 30 different PDZ classes clearly reveals 
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a high degree of amino acid residue conservation for the binding site and 
neighboring secondary structure elements, whereas the remaining regions are less 
conserved (Fig. 1). However, the interaction of the third PDZ domain of PTPN13 
(PDZ3) with its natural ligand PRK2 presented here exhibits a novel mode of 
selectivity: In PRK2, the carboxyl-terminus is constituted by a cysteine residue that 
displays an unusual motif with respect to the hydrophobic binding pocket of most 
PDZ domains known so far [18]. This discovery reveals a new mechanism of ligand 
binding with fundamental implications for the unexpectedly high variability of PDZ 
domains to select and recognize their ligands. 
 Previously, several systems to categorise PDZ domains have been 
suggested in order to describe, decipher, and even predict their ligand selectivity. 
According to Nourry et al. [19], the PDZ3 domain of PTPN13 belongs to the 
modular class I-2 of PDZ proteins. This class contains PDZ proteins that lack 
intrinsic enzymatic activity and contain additional functional domains [19]. 
Bezprozvanny et al. [20] introduced a classification system of PDZ domains that is 
based on two crucial positions in their primary structure. On the one hand, the 
amino acid immediately following the EB ȕ-sheet is denoted as position number 1. 
On the other hand, the first amino acid of WKH'%Į-helix is defined as position 
number 2. According to this system, the PDZ3 domain of PTPN13 belongs to the 
rather small Sp,p group as it is the only PDZ domain that carries an R and a Q at 
these positions in its amino acid sequence. At the same time, Vaccaro et al. [18] 
introduced a different system that classifies PDZ domains according to the four 
terminal amino acids of their respective ligands. This yields four different, 
degenerated classes. PDZ domain class I recognises ligands that carry the 
sequence motif -X-S/T-X-ĭ/Ȍ-COOH (ĭ=hydrophobic, Ȍ=aromatic, X=any amino 
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acid). According to this system, class II PDZ domains bind to -X- ĭ/Ȍ-X- ĭ/Ȍ-
COOH containing ligands, whereas class III PDZ proteins interact with a -X-D/E-X-
ĭ-COOH motif. Finally, members of class IV select PDZ ligands that contain a -X-
X-Ȍ-D/E-COOH motif [18]. Interestingly, the GLGF motif in class III PDZ domains is 
less conserved than in the other two classes, I and II (Fig. 1). This holds also true 
for the histidine residues at the beginning of the DB-ĮKHOL[$SSDUHQWO\WKHUDUHO\
occurring class III PDZ domains exhibit a higher degree of ligand promiscuity. For 
example, the neuronal nitric oxide synthase (nNos) not only binds to class III 
ligands but also interacts with carboxy-terminal PDZ ligands of nNos (CAPON) as 
well as with other PDZ domains of PSD95 [21]. Proteins of the ALP/Enigma family, 
such as the PDZ and LIM domain containing protein 4 (RIL) or Zasp, bind to both 
class III and classical class I ligands, like the carboxy-terminus of D-Actinin-2 [22]. 
Afadin (AF-6), for instance, binds to classical class III ligands, such as c-Src, to 
class I, as well as to class II ligands [19, 23]. The PDZ1 domain of Mint1 not only 
binds to N-type Ca2+ channels, class III ligands, but also to Neurexin1D, a class I 
ligand [20]. Finally, the Syntenin PDZ1 domain interacts with the D chain of the 
Interleukin 5 receptor, a class I ligand, and with the moesin-ezrin-radixinlike protein 
Merlin, a class III ligand [24]. The majority of PDZ domains identified so far belongs 
to class I, followed by members of class II. PDZ domains assigned to class III, 
however, are rare [23], [25]. According to this classification, the carboxy-terminal 
PRK2 peptide is a class III ligand, whereas APC peptide represents a class I ligand. 
It has been shown that PTPN13 is involved in the regulation of both cytoskeleton 
and intracellular vesicular transport [1], [26]. Protein kinase C-related kinase-2 
(PRK2) ± a serine/threonine kinase ± serves as a potential effector target of both 
Rho and Rac GTPases that mediates their effects on rearrangements of the actin 
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cytoskeleton. Hence, the interaction of PTPN13 with PRK2 plays a physiologically 
important role. This interaction is specifically mediated by the third PDZ domain 
(PDZ3) of PTPN13 [1], [26], [27]. Since PRK2 is the known physiological ligand of 
the PDZ3 domain of PTPN13, it is regarded as a class III representative. It is 
however also interesting to note, the PDZ3 domain of PTPN13 can also bind to 
class I ligands in vitro [1], [28]. 
 Based on the previously published NMR assignments, we now report here 
the structure in solution of the extended 12.7 kDa PDZ3 domain of PTPN13, which 
encompasses 119 residues, both in the apo-state and the PRK2-bound form [28]. 
This PDZ domain shares the highest sequence similarity with the PDZ1 domain of 
the murine PSD95. As the structural data on class III PDZ domains are rather 
sparse, the molecular basis of the interaction between the PDZ3 domain of 
PTPN13 and its physiological ligand PRK2 will further fundamentally contribute to 
our understanding of PDZ ligand selectivity in general. These data will also provide 
the basis to analyse a potential functional cross-talk between individual PDZ 
domains within the scaffolding protein PTPN13 that will help to understand the 
molecular basis for the selective recognition of ligands by the PDZ3 domain of 
PTPN13. 
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Materials and Methods 
 
Protein Expression and Purification 
Cloning, expression, and purification of the PDZ3 and PDZ2/PDZ3 tandem domain 
of murine PTPN13 has been published previously [28], [29]. The point mutant F31A 
of PDZ3 was generated through site-directed mutagenesis. The purity and integrity 
of the protein samples were checked by SDS-PAGE. Briefly, the PDZ3 construct 
used in this study consists in total of 119 amino acids, comprising 16 residues from 
the PDZ2-PDZ3 linker regions, 89 residues that constitute the canonical PDZ3 
domain, and a further 14 residues, of which 9 belong to the linker between PDZ 
domains 3 and 4; the 5 remaining residues are artefacts from cloning the GST-
PDZ3 fusion protein. For complex formation, a tenfold excess of the dodecapeptide 
MFRDFDYYIADWC derived from the last twelve carboxy-terminal amino acids of 
the protein kinase c-related protein kinase II (PRK2) was used. 
 
NMR Spectroscopy 
Typically, NMR samples contained up to 1 mM of protein in 137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, 1.4 mM KH2PO4, 0.02 % NaN3, pH 7.4, and protease 
inhibitors (complete mini, EDTA-free; Roche). NMR spectra were acquired at 298 K 
on Bruker DRX 600 and AVANCE III HD 700 spectrometers [30], [31], [32], [33]. 
Backbone assignments were obtained from three-dimensional HNCA, HN(CO)CA, 
CBCA(CO)NH, and HNCO spectra [34]. Side-chain assignments were obtained 
from three-dimensional 
1
H-
15
N HNHA [35], [36], 1H-13C HCCH-COSY [37], [38] 1H-
13C HCCH-TOCSY [38], 1H-13C NOESY-HSQC [39], 
1
H-
15
N NOESY-HSQC, and 
1H-13C-NOESY-HSQC [40] spectra. All spectra were processed with nmrPipe [41] 
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and analysed with nmrView [42] as well as CcpNmr [43]. In addition, heteronuclear 
15
N{
1
H}-NOE data were recorded in order to extract pico- to nanosecond dynamics 
[44] Additionally, 1H-13C HSQC spectra were recorded on a sample containing 15% 
13C for the stereospecific assignment of the Val and Leu methyl groups as 
described previously [45]. Intermolecular NOEs were extracted from filter-edited 
NOESY spectra and from a 1H-13C-NOESY-HSQC without 13C decoupling in the 
indirect dimension [46]. The PRK2 resonances in complex with PDZ3 of PTPN13 
were assigned based on 2D (transferred) 1H-1H NOESY as well as in a 2D 1H-1H 
double half filter (DHF) NOESY spectra [47]. Assignments have been published 
previously and have been deposited in the BioMagResBank 
(http://www.bmrb.wisc.edu) under accession numbers BMRB-16879 [28]. 
 
Structure calculation 
Peaks from the NOESY spectra were picked manually, integrated, and partially 
assigned using nmrView [42]. Then, CYANA was used for automatic NOE 
assignment and initial structure calculations were based on the unassigned NOESY 
peak lists and dihedral angle restraints as input data obtained from TALOS [48]; 
[49]. In detail, an ensemble of 20 structures was calculated from a consensus 
restraint list obtained from 20 individual automatic NOESY assignments/structure 
calculation runs. The chemical shift tolerances for NOESY peak assignments were 
set to 0.03 ppm for 1H and to 0.4 ppm for 15N and 13C. For the individual structure 
calculations, 100 random starting structures were calculated with 10,000 annealing 
steps using a torsion angle dynamics protocol. Afterwards, the experimental 
restraints were used to calculate 400 structures from an extended strand by 
simulated annealing in XPLOR-NIH [50], [51], [82]. The resulting structures were 
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further refined for energy minimization and the 50 lowest energy structures without 
NOE violations greater than 0.5  and without dihedral angle violations greater than 
5¡ were selected for final structure refinement in explicit water [52]. After water 
refinement, a validation using PROCHECK-NMR was carried out and the 20 lowest 
energy structures were chosen to represent the final structure bundle [53]. The 
statistics for the final ensembles of structures of PDZ3 from PTPN13 both in its free 
and PRK2-bound form are listed in Table 1. The final coordinates for both the apo-
PDZ3 of PTPN13 and the PRK2/PDZ3 complex have been deposited at the Protein 
Data Bank (www.rcsb.org) under the PDB-ID accession numbers 6GBD and 6GBE, 
respectively. 
 
Synthetic Peptide 
The carboxy-terminal peptide from PRK2, which comprises the sequence H-
MFRDFDYIADWC-OH and includes an acetylated amino-terminus, an acetylated 
carboxy-terminally modified derivate thereof (H-MFRDFDYIADWV-OH, C0V), as 
well as the APC-derived acetylated dodecapeptide KRHSGSYLVTSV-OH were 
purchased from JPT Peptide Technologies GmbH, Germany. Peptide stock 
solutions of at least 7 mM for titration experiments were prepared by dissolving a 
defined amount of peptide in 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.4 mM 
KH2PO4, 8 mM DTT, 0.02 % NaN3, pH 7.4. The titrations were carried out by 
adding increasing amounts of peptide stock solution to the NMR sample containing 
typically 0.1 mM of protein and NMR spectra were recorded after thorough mixing 
of the PDZ3 peptide solution. PDZ3 ligand affinity calculations based on observed 
NMR chemical shift perturbations were carried out using the Origin software 
package (OriginLab Corp., MA, USA) [54]. 
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Results 
 
Structure of apo-PDZ3 of murine PTPN13 
The NMR spectra of PDZ3 of murine PTPN13 are well dispersed (Figs. 2, 3). In 
total, 1291 NOE distance restraints, consisting of 783 short-range, 178 medium-
range, and 330 long-range NOEs, as well as 184 dihedral angle restraints were 
used during the Xplor-NIH calculations of the apo-PDZ3 structure. The precision of 
all structural ensembles of PDZ3 is high as judged by the rmsd values (Table 1). 
The root mean square deviation (rmsd) of the PDZ3 domain based on 40 backbone 
atoms primarily located in secondary structure elements (14-20, 29-31, 46-51, 56-
72, and 98-104) is 0.36  +/- 0.06  for the ensemble of 20 structures obtained 
from Xplor-NIH (Table 1; Fig. 6 a). The PDZ3 heavy atom rmsd based on the same 
selection of 40 residues as mentioned above is 0.98  +/- 0.13  for the ensemble 
obtained using Xplor-NIH (Table 1). Unstructured regions however, such as the 
GLGF motif and amino acids following the EB-ȕ-sheet in the free PDZ3 domain (but 
not in the PDZ3/PRK2 complex structure) mostly exhibit dynamics on the pico- to 
nanosecond time scale according to the analysis of the heteronuclear steady-state 
15N{1H}-NOE data and, therefore, do not converge during structure computation 
(Figs. 5,  6A, 7C). The structure in solution of apo-PDZ3 of murine PTPN13 adopts 
the canonical PDZ fold (Fig. 6a). The overall rmsd between the solutions structures 
of PDZ3 and PDZ2 (PDB-Code: 1GM1) domains of PTPN13 is 2.3  (Fig. 6b). The 
classical or canonical topology of PDZ domains is characterised by a compact, 
globular D/E fold, which contains six E-ȕ strands (EA to EF) and two D-Į helices 
(DA, DB) [4], [5]. All of these structural elements are present in apo-PDZ3 of murine 
PTPN13 except for the VKRUW((ȕ-strand: (EA: T15-F21; EB: F29-R33; EC: I46-
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L52; ED: D68-V73; EF: E96-C102; DA: P57-S61; DB: Q83-R91) (Fig. 6a). Like all 
PDZ domains, the carboxy- and amino-terminal residues of PDZ3 are located in 
close proximity on the opposite site of the ligand binding cleft. PDZ domains are 
small protein modules that consist of approximately 90 amino acids and they are 
known to bind linear carboxy-terminal motifs of their corresponding physiological 
ligand with high selectivity [6], [13], [55]. Using NMR spectroscopy, we found a 
bivalent binding selectivity for the PDZ3 domain of PTPN13. Not only does it 
recognise PRK2, a class III ligand, but also APC, a member of the ligand class I 
known to interact with PDZ2 of PTPN13 [1]. Based on NMR chemical shift 
perturbation titrations experiments using 15N-enriched PDZ3 of PTPN13, we 
determined KD values of 318 ± 47 µM for a PRK2-derived dodecapeptide and 721 ± 
148 µM for a APC-derived dodecapeptide KRHSGSYLVTSV, a tumor suppressor 
that regulates the actin cytoskeleton and is involved in cell adhesion [56] (Figs. 2, 
3). In the PDZ2/PDZ3 tandem domain however, the affinity of PDZ3 for the APC-
derived dodecapeptide dropped to approximately 1 mM. The structure of PDZ3 
from PTPN13, both in its free and peptide-complex form, now further expands the 
molecular basis of how class III PDZ domains, select, interact, and recognise their 
physiological class II ligands, such as PRK2, at atomic resolution. 
 
Structure in solution of the PDZ3 domain of murine PTPN13 in complex with 
the carboxy-terminal peptide derived from PRK2 
The rmsd of the PDZ3/PRK2 complex based also on 40 backbone atoms (15-20, 
29-32, 46-52, 63-77, and 96-103) is 0.51  +/- 0.09  for structures computed using 
Xplor-NIH (Table 1; Fig. 7). Based on the heavy atoms of those selected atoms of 
the PDZ3/PRK2 complex, the rmsd of the complex is 1.16  +/- 0.17  for the 
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ensemble generated by Xplor-NIH (Table 1; Fig. 7). The slightly lower precision of 
the PDZ3/PRK2 complex structure in comparison to the structure of apo-PDZ3 can 
be attributed to the micromolar affinity of PDZ3 for PRK2 as this required a molar 
excess of the PRK2 peptide to PDZ3 of 1:10. For the calculation of the PDZ3/PRK2 
complex, 1170 NOE distance restraints, comprising 779 short-range, 129 medium-
range, 246 long-range, and 14 intermolecular NOEs, as well as 178 dihedral angle 
restraints could be extracted from NOESY spectra. The 14 intermolecular NOEs 
(Fig. 7 A, B) could be detected between residues G26, S30-S32, Q83, I87, and L90 
of PDZ3 and C0, W-1, D-2, I-4 of PRK2 (Fig. 7 A, B). These intermolecular NOEs 
clearly define the interaction site as well as the binding mode of the PRK2-derived 
peptide and the PDZ3 domain from PTPN13 (Fig. 7 B). In comparison to the 
calculation of apo PDZ3, the number of long-range NOEs declined from 330 to 246. 
Nonetheless, the overall precision of structures is still high and allows for the 
analysis of the molecular basis of PRK2 recognition by PDZ3 of PTPN13. Like its 
apo form, the compact globular Į/ȕ fold PDZ3 of murine PTPN13 in complex with 
PRK2 consists of five ȕ-strands and two Į-helices (Fig. 7). In contrast to the apo-
PDZ3 structure, GLGF motif and most of the amino acids following the EB-ȕ-sheet 
in the PDZ3/PRK2 complex structure are rigidified as they do not exhibit dynamics 
on the pico- to nanosecond time scale according to the analysis of the 
heteronuclear steady-state 15N{1H}-NOE data (Fig. 5). 
 
Structural basis of the recognition of the PRK2 carboxy-terminus by PDZ3 
The structure of the PDZ3/PRK2 complex presented here reveals the molecular 
basis of the interaction between the carboxy-terminal peptide of PRK2 and the 
PDZ3 domain of PTPN13 at atomic resolution (Fig. 7 B, C). Complex formation is 
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mainly mediated through the highly conserved GLGF motif found in these PDZ 
proteins, which stabilizes the carboxylic function, denoted as P0, of the PDZ-ligand 
carboxy-terminus itself. This interaction is accomplished by three hydrogen bonds 
between carboxylic oxygen atoms from the peptide ligand and LGF amide groups 
located within the 3'=SURWHLQ¶VGLGF motif. In some PDZ domains additional 
interactions with their ligands have been described, facilitated by a conserved K or 
R side chain positioned four amino acids in front of the GLGF motif towards the 
amino-terminus (K/RXXXGLGF) [4]. In PDZ/peptide complexes, the last four 
carboxy-terminal amino acids from the ligand bind to a cleft of the PDZ domain 
located between the EB-ȕ sheet and the DB-Į helix and thereby extend the 
antiparallel E-ȕ sheet [4], [57]. While the amino acid side chains in position P-1 and 
P-3 of the ligand point away from the PDZ binding cleft, the amino acid side chains 
of P0 und P-2 are oriented towards the PDZ binding pocket. Therefore, positions 
P0 und P-2 influence and/or contrROWKHOLJDQG¶VVHOHFWLYLW\IRU3'=GRPDLQVto a 
greater extend [58]. According to NMR titration experiments, the KD value for the 
PDZ3/PRK2 complex is at the lower end of affinities reported for PDZ/peptide 
interactions ([59]) (Fig. 3). Further, we also show here that this PDZ3 domain also 
binds to the carboxy-terminus of APC, albeit with an extremely low affinity (Fig. 2). 
The structure of the PDZ3/PRK2 complex now reveals some particular features that 
explain this lower affinity and the observed promiscuity of PDZ3 of PTPN13, but it 
can now also explain as to why PDZ3 selects PRK2 over APC as a ligand. Firstly, 
the GLGF loop of class III PDZ domains is less conserved. Secondly, numerous 
PDZ domains are characterized by an extension of the classical GLGF motif to 
K/RXXXGLGF that further stabilizes the interactions with their ligands through 
coordinating a water molecule. A characteristic NOE network supporting this 
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extended interaction between the PDZ3 domain of PTPN13 and PRK2 however, 
could not be identified. In the NMR ensemble of the PDZ3/PRK2 complex, the side 
chain of the conserved K22 of PDZ3 does not point towards the PRK2 ligand. 
Instead, the side chain of K22 is partly rotated out of the binding site upon 
interacting with PRK2 to provide more space in the binding cleft of PDZ3 of 
PTPN13 (Fig. 8). An analysis of all class III PDZ3 domains published to date 
suggests that the stabilization of the bound ligand through the amino acid side 
chain of a conserved K or R located in the extended K/RXXXGLGF motif only plays 
a minor role. Structures of PDZ domains from nNos (PDB-Code: 1B8Q) and Afadin 
(PDB-Code: 2AIN) show similar side chain conformations of K or R like K22 in 
PDZ3 of PTPN13. The same holds true even for the apo-PDZ structures of RIL 
(PDB-Code: 2EEG) and, in part, Mint1 (PDB-Code: 1U37), whose conserved K or 
R side chains also do not point towards the peptide ligand binding site. 
Interestingly, this amino acid position is not even conserved in the PDZ domains of 
Zasp (PDB-Code: 1RGW) and Syntenin1 (PDB-Code: 1W9O). Another notable 
feature of the PDZ3 domain of PTPN13 is F31, positioned two amino acids 
carboxy-terminal after the GLGF motif (GLGFSF) (Fig. 1). In contrast to the other 
sequences from all PDZ domain classes aligned in Fig. 1, PDZ3 of PTPN13 
contains an aromatic side chain at this position, whereas an aliphatic residue is 
usually found a this position of the EB-ȕ-sheet (Fig. 1, 9). This results in a rather 
shallow binding cleft between the EB-ȕ-sheet and the DB-Į helix of the PDZ3 
domain from PTPN13 in comparison to other PDZ domains (Fig. 9). The aromatic 
ring system of F31 lies within the plane of the EB ȕ-strand and, together with V86 
and I87, flattens the ligand binding cleft of PDZ3 of PTPN13 to further reduce its 
binding interface area (Fig. 9). A F31A mutant of PDZ3 destabilizes the PDZ fold 
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and/or lead to aggregation of PDZ3 and a dramatically reduced ligand affinity as 
judged from 1H-15N HSQC NMR spectra (Fig. 4). The interaction between PDZ 
domains and their ligands is in particular mediated by a hydrogen bond between 
the amino acid side chain at position P-2 of the peptide ligand and a side chain NH 
of a conserved histidine residue located at the beginning of DB Į-helix in the PDZ 
protein as numerous studies have shown [18], [20]. Noteworthy, this histidine 
residue is not present in PDZ3 of PTPN13 (Fig. 1). Instead, this PDZ domain 
contains a glutamine residue (Q83) at this position, which is capable of stabilizing 
the side chain carboxylate function of the ligand in position P-2 of PRK2 through a 
hydrogen bond (Figs. 1, 8-10). Although the PRK2/PDZ3 interaction principally 
differs at this position from the classical PDZ-ligand binding mode, it is yet 
functionally conserved. The orientation of the PRK2 peptide in the binding pocket of 
PDZ equals the canonical binding mode (Figs. 1, 8-10). The free carboxy-terminus 
of the ligand cysteine residue located at position P0 (C0) is stabilised by hydrogen 
bonds to the backbone amide groups of L27 and G28, whereas the carbonyl group 
of F29 forms a hydrogen bond with the amide group of C0 (Figs. 3, 8-10). The 
ligand side chains of cysteine and aspartate at positions P0 and P2 are oriented 
towards the PDZ binding cleft, whereas those in P-1 and P-3, tryptophan and 
alanine are facing towards the solvent (Figs. 1, 8-10). A mutant PRK2 peptide with 
valine instead of cysteine in P0 (C0V) binds to PDZ3 with 38% higher affinity (Fig. 
S2). Apparently, PDZ3 of murine PTPN13 not only tolerates ligands carrying a 
carboxy-terminal cysteine but also valine. The cysteine of PRK2 contacts N23 and 
G26 in PDZ3. The bulky tryptophan side chain in P-1 can probably not be 
accommodated by the PDZ3 ligand binding site that contains three large side 
chains, F31, V86, and I87. The solvent exposed P-1 tryptophan rather packs 
 17 
against L27 of PDZ3 and the alanine side chain in position -3 of the PRK2 ligand. 
The aspartate side chain in position P-2 of the PRK2 ligand is buttressed by a 
hydrogen bond originating from the Q83 side chain of the DB Į-helix (Figs. 1, 8-10). 
In the nNos structure (PDB-Code: 1B8Q), the P-2 aspartate side chain is stabilised 
by a tyrosine hydroxyl group. In the ZO1 PDZ3 in complex with a phage-derived 
class peptide (PDB-Code: 4Q2Q), the P-2 aspartate side chains points away from 
the PDZ binding cleft leading to non-FDQRQLFDOEHQWDQGWKHUHIRUHQRWH[WHQGHGȕ-
sheet ligand conformation [17]. Taken together, the interaction between PDZ3 and 
the PRK2 carboxy-terminus comprises five PRK2 residues and extends until 
position P-4 as its Ile side chain is in proximity to the side chains of E34 and I87 in 
PDZ3. In comparison to most canonical PDZ class I, II, and even the few known 
class III interactions, the PDZ3/PRK2 binding interface is thus lengthened by one 
ligand residue [60]. 
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Discussion 
Like PTP, PH, SH2, and SH3 domains, PDZ domains are important cellular 
mediators of protein-protein interactions. PDZ domain-containing proteins play 
important roles in complexing and anchoring transmembrane proteins as well as in 
morphogenesis [13]; [15]; [61]. The human protein tyrosine phosphatase PTPN13 is 
also involved in numerous cellular processes, such as regulation of cytokinesis and 
signal transduction [62]; [63]; [64]; [65]; [66]. PTPN13 harbours five consecutive 
PDZ domains, termed PDZ1 to PDZ5. Based on yeast two-hybrid assays and co-
immunoprecipitation experiments from transfected HeLa cells, PDZ3 of PTPN13 
has been described to interact with protein kinase PRK2, a regulator of the cell 
cycle [1], [27]. 
 Several approaches have been described to classify PDZ domains and their 
ligands [18], [19], [20], [23], [25], [57], [67], [68], [69]. However, the analysis focused 
on PDZ domains that significantly differ from PDZ3 of PTPN13 in almost all cases. 
Therefore, our structural studies shed light on the mechanism of how PDZ3 selects 
and bind its physiological ligand at atomic resolution. According to Stiffler and 
Chen, PDZ3 of PTPN13 qualifies as a class III PDZ domain [67] and 16 crucial 
amino acids constitute the peptide binding cleft: G26, L27, G28, F29, S30, F31, 
S32, R33, K50, K51, F53, Q83, Q84, I87, and T93. This peptide binding pocket is 
corroborated by 14 intermolecular NOEs that include G26, S30-S32, Q83, I87, and 
L90 of PDZ3 and C0, W-1, D-2, I-4 of PRK2 (Fig. 7 B). Based on NMR chemical 
shift perturbation experiments, we could show that the affinity of PDZ3 from 
PTPN13 is 318 ± 47 µM for a PRK2-derived dodecapeptide and 721 ± 148 µM for a 
APC-derived dodecapeptide KRHSGSYLVTSV, a tumor suppressor that regulates 
the actin cytoskeleton and is involved in cell adhesion [56]. The biggest difference 
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between the PDZ2 and PDZ3 binding clefts from PTB-BL is indeed F31 in PDZ3, 
which is a valine in PDZ2 and thus renders its binding pocket more open (Fig. 9). 
More importantly, Q83 in PDZ3 is changed to His78 in PDZ2. These two changes 
might account for PDZ3 selecting PRK2 over APC as the interaction between Q83 
and P-2 of the ligand peptide is presumably optimised in PDZ3 for PRK2 that bears 
D in P-2 instead of T as found in APC (Fig. 10). In spite of the low affinity, APC 
could still be of regulatory and therefore physiological significance for PDZ3 of 
PTPN13 as an increasing number of identified weak protein complexes emerge as 
essential components in physiological processes [70]. According to Stiffler and 
Chen, I-4, A-3, D-2, W-1, and C0 have been identified as important residues in 
PRK2 ± a class III ligand ± that is recognized by PDZ from PTPN13. For the class I 
ligand APC, residues L-4, V-3, T-2, S-1, and V0 are predicted to be important for 
interaction with PDZ3 from PRP-BL [67]. 
 According to Kalyoncu and coworkers, PDZ domains can be classified 
according to three conserved amino acid sequence elements [69]. The first element 
is located in the PDZ-peptide binding interface that comprises the GLGF loop [61] 
and the second one is found at the end of the DB-Į-helix [71]. Surprisingly, the 
highly conserved histidine ± or any other hydrogen bond donor for the P-2 ligand 
amino acid ± positioned at the beginning of the DB-Į-helix does not play a 
significant role in this analysis. This is presumably due to the fact that the two 
neighbouring positions of this histidine residue are much less conserved. The third 
conserved element, which is located in front of the ED-ȕ-sheet [72], is not part of 
the peptide binding interface of PDZ domains either. The importance of this 
element for ligand selection is still not fully understood but it has been suggested to 
participate in the dimerisation of PDZ domains [72]. It is interesting to note, that 
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PDZ3 of PTPN13 does contain all of these three conserved elements although it is 
a class III member, a class not covered by the analysis reported by Kalyoncu [69]. 
In PDZ3 of PTPN13, these three elements correspond to the following residues: 
G28/F29 of the GLGF loop, L90/R91 of the DB-Į-helix, and G67/D68 preceding the 
ED-ȕ-sheet. In spite of an identical topology, subtle structural differences can be 
even found for the carboxylate-binding loop and the DB-ĮKHOL[RIWKH3'=OLJDQG
pocket. Together with the differences in the amino acid sequence of the 
carboxylate-binding loop, this structural divergence could contribute to the selection 
of PRK2 over APC by PDZ3 from PTPN13. The rmsd for the backbone atoms of 40 
amino acids mainly located in secondary structure elements of the structure 
ensemble of PDZ3 is 0.43  +/- 0.12  and the rmsd of the heavy atoms of the 
these 40 amino acids is 0.90  +/- 0.14 . In the structure ensemble of the 
PDZ3/PRK2-complex, the rmsd for the backbone atoms of 40 amino acids mostly 
located in secondary structure elements is 0.51  +/- 0.17  and the rmsd of the 
heavy atoms of the these 40 amino acids is 1.16  +/- 0.17  (Fig. 7). Noteworthy, 
the W-1 of the PRK2 peptide bound to PDZ from PTPN13 is solvent exposed. The 
aromatic ring system of F31 lies within the plane of the EB ȕ-strand and flattens the 
ligand binding cleft of PDZ3 of PTPN13 to further reduce its binding interface area 
(Fig. 9). Presumably, this contributes to the rather low micromolar binding affinity of 
PDZ to class III ligands in comparison to other PDZ domains. The mutation 
experiments clearly show on the one hand that the PRK2 C0V mutant peptide binds 
to PDZ3 with a slightly higher affinity. On the other hand, the F31A mutant of PDZ3 
destabilizes the PDZ fold and/or leads to aggregation of PDZ3 and a dramatically 
reduced ligand affinity with a KD value well above 1 mM (Fig. 4 A, B). The former 
shows that the PDZ3 binding cleft is capable of accommodating the isopropyl side 
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chain of valine, which ± in contrast to the wildtype PRK2 cysteine ±apparently 
contributes to increased van der Waals contacts within the PDZ3 binding pocket 
that strengthen the PDZ3/PRK2 interaction. This is in accordance with a previous 
phage display study that found a preference of PDZ3 for valine in position 0 [84]. 
The latter suggests that F31 not only changes and flattens the PDZ binding cleft to 
determine binding specificity but is also an important core residue of PDZ3 that 
stabilises both the binding pocket and even the entire PDZ3 fold. Taken together, 
the mutation data indeed underline the crucial role of both F31 from PDZ3 and C0 
from PRK2 in determining the binding affinity of the PDZ3/PRK2 complex. 
Nonetheless, the interaction between PDZ3 and the PRK2 carboxy-terminus 
ranges from the carboxy-terminal cysteine in P0 to isoleucine in position P-4, which 
is surrounded by E34 and I87 from PDZ3. In comparison to class I and II ligand 
recognition, this class III PDZ3/PRK2 interface is extended, which concurs with 
previous observations [57], [60], [67], [73]. Upon binding, the carboxy-terminus of 
PDZ domain ligand adopt an E-ȕ strand conformation that extends the existing anti-
parallel, two-stranded E-sheet found in the apo-PDZ domain ± a mechanism 
referred to as E-strand addition [74]. However a complete NOE pattern indicative of 
an E-strand could not be extracted from the NOESY spectra of the PDZ3/PRK2 
complex. Nonetheless the PRK2 peptide also adopts an extended conformation 
upon binding to PDZ3 (Fig. 7). Interestingly, the structural differences between the 
free and PRK2-bound PDZ3 domain from PTPN13 are not located in and near the 
peptide-binding cleft but further extent to remote regions in this PDZ domain (Figs. 
8, 9). In addition, the titration of the APC peptide with the PDZ2/3 tandem domain 
yields a KD value of approximately 1 mM and thus an even weaker interaction in 
comparison to the single PDZ3 domain (Fig. S1 a, b). Apparently, not only binds 
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APC to PDZ2 but this also weakens the interaction between PDZ3 and APC 
despite the linker of 44 residues between both PDZ domains in PTPN13. This could 
suggest allosteric effects mediated by PDZ2/PDZ3 domain interactions to 
potentially modulate ligand recognition of and binding to PTPN13, a feature not 
unprecedented in PDZ-ligand interactions [75], [76], [77], [78], [79], [80], [85]. For 
PTPN13, however, future experiments are required to prove this hypothesis further. 
 
 
 
In summary, the structure in solution of PDZ3 from murine PTPN13 and in 
complex with a PRK2-derived carboxy-terminal peptide expand the currently rather 
limited knowledge about the interaction between a class III PDZ domain and a class 
III peptide ligand. The structures presented here shed light on a molecular level as 
to why PDZ3 of PTPN13 exhibits a rather weak affinity for its class I and III ligands, 
APC and PRK2. Recently, a study on the binding promiscuity of the PDZ domain 
from the neuronal NO Synthase reported that it even binds to ligands of all three 
classes [60]. Lastly, the apo- and complex structures of PDZ3 from PTPN13 now 
provide the molecular basis for further studies on its rather low level of ligand 
selectivity and on its low-affinity for new (peptide) ligands. Finally, our study 
complements the wealth of structural information previously published for the PDZ2 
domain of PTPN13 [81]; [3]. In total, PTPN13 contains five PDZ domains that are 
separated by linkers of different length and it has been suggested that PTPN13 
acts as a scaffolding protein in the cell, because each PDZ domain can interact with 
different ligands [1]. Future studies will have to address the important question as to 
whether the relative PDZ1-5 domain orientations differ from one another upon 
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binding to various ligands. Evidently, this will have profound functional, PDZ 
domain-mediated physiological implications for PTPN13. 
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Conclusion 
PDZ domains are common protein-protein-interaction-domains sharing a globular 
fold. They preferentially bind the carboxy-termini of their ligand proteins with high 
specificity. Since PDZ domain proteins often consist of more than one PDZ domain 
they are referred to as scaffolding proteins, harbouring large macromolecular 
protein complexes. These complexes are involved in numerous regulatory cellular 
processes. PDZ3 of PTPN13 belongs to the unusual class III PDZ domains, which 
bind to ligands harbouring the carboxy-terminal motif -X-D/E-X-ĭ-COOH. The 
structures PDZ3 of murine PTPN13 bound to the carboxy-terminus of PRK2 now 
represent a rare example of selective class III ligand recognition by a PDZ domain 
now provide a basis for the detailed structural investigation of the promiscuous 
interaction between the PDZ domains of PTPN13 and of their interaction with 
ligands. PDZ3 of PTPN13 adopts the common D/E-fold without the short EE-strand. 
PDZ3 of PTPN13 binds five carboxy-terminal amino acids of PRK2 via a groove 
located between the EB-strand and the DB-helix to achieve selectivity. The PRK2 
peptide binds to the canonical PDZ3 binding cleft in an elongated manner and its 
amino acid side chains in position P0 and P-2, cysteine and aspartate, face the 
groove between EB-strand and DB-helix of PDZ3, whereas the PRK2 side chains 
of tryptophan and alanine located in position P-1 and P-3 point away from the 
binding pocket. These PDZ3 structures now provide a molecular basis for the 
design of biochemical experiments and molecular dynamics studies in the future 
that will ultimately help to decipher PTPN13¶VVFDIIROGLQg function(s) and selectivity 
determinants of PDZ domains for (novel) class III ligands in general. In addition, the 
structures of PDZ3, both in its free and PRK2-complexed form, might ultimately 
contribute to the development of low molecular weight antagonists that could even 
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act on the protein kinase C-related kinase-2 (PRK2) signalling pathway to modulate 
rearrangements of the actin cytoskeleton. 
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Table 1: NMR statistics of the final structural ensembles of apo-PDZ3 and the 
PDZ3/PRK2 complex. 
 
 
 
             
Structure calculation (XPLOR-NIH)   apo-PDZ3 PDZ3/PRK2 complex 
Experimental restraints          
Distance restraints      
Total       1291  1170 
Short-range      783  779 
Medium      178  129 
Long-range      330  246 
Inter-molecular      0  14 
'LKHGUDODQJOHUHVWUDLQWVĳȥ   184  178 
Structural statistics of the final 20 lowest-energy structures      
RMSD [] 
Backbone      0.36 +/- 0.06 0.51 +/- 0.09 
Heavy atoms      0.98 +/- 0.13 1.16 +/- 0.17 
rmsd range: apo-PDZ3:    14-20,29-31,46-51,56-72,98-104 
PDZ3/PRK2 complex:   15-20,29-32,46-52,63-77,96-103 
Final energies [kcal mol-1] 
ETotal       102.14  105.52 
ENOE       7.91  8.27 
EANGL       80.67  84.50 
EBOND       2.02  1.96 
EDIHE       0.18  0.08 
EIMPR       9.70  9.74 
EVDW       2.61  2.03 
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Restraint violations 
NOE distances violated > 0.5     0  0 
Dihedral angles violated > 5¡    0  0 
RMSD from idealised geometry (WHATCHECK) 
Bond lengths []     0.010  0.010 
Bond angles [¡]      1.602  1.611 
Ramachandran statistics (PROCHECK-NMR) [%]       
Favoured regions     68.7  70.4 
Additional allowed regions    29.5  26.7 
Generously allowed regions    1.8  2.3 
Disallowed regions     0.1  0.5   !
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Figures and Figure Captions: 
 
 
Fig. 1: (A) The modular organisation of murine PTPN13 (UNIPROT accession 
number Q64512) comprises a KIND domain (residues 3-190) at its amino-terminus 
(N), followed by a FERM domain (residues 565-865), five PDZ domains (PDZ1: 
residues 1084-1170; PDZ2: residues 1357-1442; PDZ3: residues 1491-1579; 
PDZ4: residues 1764-1845; PDZ5: residues 1857-1942), and a carboxy-terminal 
(C) protein tyrosine phosphatase domain (TPD: residues 2180-2434). (B) 
Sequence alignment of 30 different PDZ domains from all three classes. The 
coding region of the PDZ3 domain construct from from PTPN13 used in this study 
comprises amino acid residues 1475 to 1588 (highlighted with an asterisk). 
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Fig. 2: In the upper part, a 2D 1H-15N-HSQC of the PDZ3/APC complex at different 
molar ratios given as an insert, 600 MHz, and 298 K is shown. Residue specific 
assignments of backbone 1H and 15N frequencies are indicated. Signals connected 
by horizontal lines correspond to side chain amide groups of asparagine and 
glutamine residues. The plot of the chemical shift dispersion versus the amino acid 
sequence is shown in the lower left corner. The lower right corner displays the 
curve fitting of amino acid S30 for the PDZ3/APC titration. 
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Fig. 3: In the upper part, a 2D 1H-15N-HSQC spectra of the PDZ3/PRK2 complex at 
different molar ratios given as an insert, 600 MHz, and 298 K is shown. Residue 
specific assignments of backbone 1H and 15N frequencies are indicated. Signals 
connected by horizontal lines correspond to side chain amide groups of asparagine 
and glutamine residues. The plot of the chemical shift dispersion versus the amino 
acid sequence is shown in the lower left corner. The lower right corner displays the 
curve fitting of amino acid S32 for the PDZ3/PRK2 titration. 
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Fig. 4: (A) 2D 1H-15N-HSQC spectra of wildtype PDZ3 titrated with a PRK2 mutant 
peptide C0V recorded at 700 MHz and 298K. The insert displays the curve fitting of 
amino acid S32 for the PDZ3/PRK2C0V titration. The colour coding of spectra is 
the same as in Fig. 2 and 3. (B) 2D 1H-15N-HSQC spectra of PDZ3 F31A titrated 
with a PRK2 mutant peptide C0V recorded at 700 MHz and 298K. Again, the colour 
coding of spectra is the same as in Fig. 2 and 3. 
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Fig. 5 (A) Plot of the heteronuclear steady-state 
15
N{
1
H}-NOE values versus 
residue number for apo-PDZ3 sample. The secondary structure elements are 
colored as follows: Į-helices are highlighted in blue and ȕ sheets in green. (B) Plot 
of the heteronuclear steady-state 
15
N{
1
H}-NOE values versus residue number for 
the PDZ3/PRK2 complex. Residues supposed to be flexible exhibit 
15
N{
1
H}-NOE 
values below 0.6. The secondary structure elements are colored as follows: Į-
helices are highlighted in blue and ȕ sheets in green (EA: T15-F21; EB: F29-R33; 
EC: I46-L52; ED: D68-V73; EF: E96-C102; DA: P57-S61; DB: Q83-R91). Proline 
residues are depicted in black. 
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Fig. 6. (A) Ribbon representation of the Xplor-NIH structural ensemble calculated 
for apo-PDZ3 of PTPN13 generated with PyMOL (www.pymol.org). The left column 
depicts the apo-PDZ3 domain of PTPN13 in a ribbon representation. In right 
column, a line representation of the structure in the same orientation is shown. The 
high precision of the structural ensemble is clearly visible. For the rmsd values refer 
to Table 1. The secondary structure elements are colored as follows: Į-helices are 
highlighted in blue and ȕ sheets in green. The orientation of the structural ensemble 
is such that the PDZ binding interface is shown with EB-ȕ-sheet located on the left 
hand side and the DB-Į-helix on the right hand side. Both, the unstructured amino- 
and carboxy-terminus are not shown for clarity. This figure was generated using 
PyMOL (www.pymol.org). (B) Superposition of the apo-PDZ3 (shown in sandy 
colour) domain from PTPN13 with its PDZ2 domain (PDB-Code: 1GM1, shown in 
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red). The orientation between the left and right orientation differs by a rotation of 
90¼ to the left. The overall rmsd is 2.3 . This figure was generated using PyMOL 
(www.pymol.org). 
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Fig. 7: (A) Strip plot of a 1H-13C NOESY-HSQC spectrum with (left panel) and 
without (right panel) 13C decoupling in the indirect dimension. A representative 
intermolecular NOE between Hį of L90 from 15N, 13C isotopically-enriched PDZ3 
and Hȕ of C0 from PRK2 is highlighted by an orange horizontal line. The 
intermolecular NOE does not experience any splitting due to the natural abundance 
of 13C in the PRK2 peptide (right panel). (B) Surface representation of the 
PDZ3/PRK2 complex. The PDZ3 surface is in shown in yellow. The PRK2 peptide 
is depicted as a line in green. Residues of PDZ3 for which intermolecular NOEs 
could be detected are highlighted in red and labelled (G26, S30-S32, Q83, I87, and 
L90). Residues of PRK2 for which intermolecular NOEs could be identified are 
highlighted in blue (C0, W-1, D-2, I-4). (C) Ribbon representation of all three 
structural ensembles calculated for PDZ3 of PTPN13 in complex with a PRK2-
derived carboxy-terminal peptide. The PDZ3 domain of PTPN13 is shown in ribbon 
representation. The high precision of the structural ensemble calculated using 
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Xplor-NIH is clearly visible. The secondary structure elements are colored as 
follows: Į-helices are highlighted in blue and ȕ sheets in green. The orientation of 
the structural ensemble is such that the PDZ binding interface is shown with EB-ȕ-
sheet located on the left hand side and the DB-Į-helix on the rind hand side. Both, 
the unstructured amino- and carboxy-terminus have been omitted for clarity. The 
five structured amino acids located at the carboxy-terminus of the PRK2 peptide 
are colored in orange. Figs. 7B and 7C were generated using PyMOL 
(www.pymol.org). 
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Fig. 8: Detailed ribbon representation of the peptide binding cleft of apo-PDZ3 
(shown in sandy colour) and in complex with the PRK2 peptide (shown in green). 
K22 of PDZ3 and C0 of PRK2 are shown in ball-and-stick representation. On the 
left hand side, a direct view onto the binding pocket is shown. On the right hand 
side, the PDZ3 domain is rotated about 90¡ to the left in order to reveal the steric 
demand of the carboxy-terminal C0 of the PRK2 peptide as well as the orientation 
of the K22 side chain. Upon interaction with the PRK2 carboxy-terminus, the K22 
side chain of the PDZ3 located at the rear of the empty binding pocket partly flips 
out. This figure was generated using PyMOL (www.pymol.org). 
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Fig. 9: Orientation of the F31 side chain. This figure was generated using PyMOL 
(www.pymol.org). 
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Fig. 10: Molecular recognition of the PRK2-derived dodecapeptide 
MFRDFDYYIADWC (shown as sticks) by PDZ3 from PTPN13. The charge 
distribution is shown for residues of PDZ3 (shown in sticks) that contact the PRK2 
peptide. This figure was created using LigPlot+ [83] and PyMOL (www.pymol.org). 
 
